Azione MDGL MADRIGAL PHARMACEUTICALS, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Madrigal Pharmaceuticals, Inc.

Azioni

MDGL

US5588681057

Mercato chiuso - Nasdaq
Altri mercati azionari
 22:00:00 02/05/2024 		Variaz. 5gg Var. 1 gen.
216 USD +2,59% Grafico intraday di Madrigal Pharmaceuticals, Inc. +5,57% -6,63%
23/04 MADRIGAL PHARMACEUTICALS, INC. : downgrade da BofA Securities ZM
23/04 MADRIGAL PHARMACEUTICALS, INC. : il rating passa da Buy a Sell secondo BofA Securities ZM

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Nonalcoholic Steatohepatitis Market to Observe Impressive Growth During the Forecast Period | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Madrigal Pharmaceuticals
Madrigal Statement on the Passing of Dr. Stephen Harrison
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
6 Stocks Positioned to Soar as Investors Focus on MASH
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals Insider Sold Shares Worth $658,258, According to a Recent SEC Filing
Madrigal Pharmaceuticals Insider Sold Shares Worth $6,467,491, According to a Recent SEC Filing
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Madrigal Pharmaceuticals Says Rezdiffra Available in US
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,214,998, According to a Recent SEC Filing
Madrigal Pharmaceuticals Insider Sold Shares Worth $8,218,630, According to a Recent SEC Filing
Madrigal Pharmaceuticals Insider Sold Shares Worth $2,832,335, According to a Recent SEC Filing
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
EE.UU. - Valores a seguir en Wall Street (actualizado)
Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -
Madrigal Pharmaceuticals : lève 600 millions de dollars pour le lancement de son Rezdiffra
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione MDGL
  4. Notizie Madrigal Pharmaceuticals, Inc.
  5. Altre lingue